4SC AG
Biopharmaceutical company with no products under development or operational business.
VSC | F
Overview
Corporate Details
- ISIN(s):
- DE000A3E5C40
- LEI:
- 391200QOKN7LGVP0RQ86
- Country:
- Germany
- Address:
- Fraunhoferstr. 22, 82152 Planegg
- Website:
- https://www.4sc.com/
- Sector:
- Manufacturing
Description
4SC AG is a biopharmaceutical company that formerly focused on the research and development of small-molecule drugs for cancer treatment. The company's strategy centered on addressing diseases with high unmet medical needs by developing innovative therapies that targeted epigenetic mechanisms of action. According to the company's official statements, it currently has no products under development and no operational business.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2018-10-26 07:30 | English | HTML • 1.8 KB | |||
| 2018-10-26 00:00 |
Datum:26.10.2018
|
German | HTML • 11.1 KB | ||
| 2018-10-25 07:31 |
4SC provides Q3 business update and outlook
|
English | HTML • 12.8 KB | ||
| 2018-10-25 00:00 |
Q3 statement / Q3 financial report 2018
|
English | PDF • 289.3 KB | ||
| 2018-09-20 07:30 |
4SC AG: Domatinostat plus chemotherapy - Overcoming drug resistance
|
English | HTML • 14.0 KB | ||
| 2018-09-12 07:30 |
4SC AG: 6 upcoming conferences and roadshows
|
English | HTML • 9.1 KB | ||
| 2018-08-15 07:30 |
4SC AG: FDA approves IND application for domatinostat (4SC-202) in melanoma
|
English | HTML • 12.2 KB | ||
| 2018-08-10 00:00 |
Half-yearly financial report 2018
|
English | PDF • 528.1 KB | ||
| 2018-08-09 07:30 |
4SC provides Q2 and H1 2018 update
|
English | HTML • 13.0 KB | ||
| 2018-08-02 07:30 |
4SC AG: Conference call to be hosted on 9 August 2018 to present the half-year …
|
English | HTML • 8.9 KB | ||
| 2018-07-31 07:30 |
First patient enrolled in 2nd dose cohort of Phase Ib/II study SENSITIZE of dom…
|
English | HTML • 13.9 KB | ||
| 2018-07-18 07:30 |
4SC AG: Stifel Nicolaus Europe initiates research coverage on 4SC with a buy ra…
|
English | HTML • 9.6 KB | ||
| 2018-07-03 07:30 |
4SC AG: Positive safety review of 4SC's Phase Ib/II SENSITIZE study of domatino…
|
English | HTML • 14.1 KB | ||
| 2018-06-28 07:30 |
4SC AG: New data supports resminostat's mechanism of action in CTCL maintenance…
|
English | HTML • 17.5 KB | ||
| 2018-05-22 07:30 |
4SC AG: 9 upcoming conferences and roadshows
|
English | HTML • 9.8 KB |
Automate Your Workflow. Get a real-time feed of all 4SC AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for 4SC AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for 4SC AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
